Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: An optical coherence tomography study

Oswaldo Ferreira Moura Brasil, Scott D. Smith, Anat Galor, Careen Y. Lowder, Jonathan E. Sears, Peter K. Kaiser

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Aim: To evaluate the predictive factors for visual outcome after intravitreal triamcinolone acetonide injection to treat refractory diabetic macular oedema (DME). Methods: A retrospective chart review of patients with DME who met the following inclusion criteria was performed: clinically significant diabetic macular oedema, receipt of a 4 mg/0.1 ml intravitreal triamcinolone acetonide injection and an optical coherence tomography (OCT) of the macula performed up to 10 days before injection. All patients received a full ophthalmic examination including best-corrected Snellen visual acuity (VA). The main outcome measure was the mean change in vision 3 months after injection. Results: Data from 73 eyes of 59 patients were analysed. After a mean follow-up of 324 days, the mean change in vision was -0.075 logarithm of minimum angle of resolution (logMAR) units, with 27.3% improving ≥3 lines, 6.8% declining ≥3 lines and 60.2% remaining stable within 1 line of baseline vision. Statistical analysis was performed using multivariate generalised estimating equations on the basis of data from 52 eyes of 42 patients. Factors associated with an improvement in vision 3 months after injection were worse baseline VA (-0.27 logMAR units/unit increase in baseline VA, p = 0.002) and presence of subretinal fluid (-0.17 logMAR units, p = 0.06). The presence of cystoid macular oedema negatively affected the visual outcome (0.15 logMAR units, p = 0.03). In addition, the presence of an epiretinal membrane (ERM) was associated with less visual improvement. ERM modified the effect of baseline VA as demonstrated by a significant interaction between these two variables (0.34 logMAR units/unit increase in baseline VA, p = 0.04). Conclusions: OCT factors and baseline VA can be useful in predicting the outcomes of VA 3 months after intravitreal triamcinolone acetonide injection in patients with refractory DME.

Original languageEnglish
Pages (from-to)761-765
Number of pages5
JournalBritish Journal of Ophthalmology
Volume91
Issue number6
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Triamcinolone Acetonide
Macular Edema
Optical Coherence Tomography
Visual Acuity
Injections
Epiretinal Membrane
Subretinal Fluid
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema : An optical coherence tomography study. / Brasil, Oswaldo Ferreira Moura; Smith, Scott D.; Galor, Anat; Lowder, Careen Y.; Sears, Jonathan E.; Kaiser, Peter K.

In: British Journal of Ophthalmology, Vol. 91, No. 6, 01.06.2007, p. 761-765.

Research output: Contribution to journalArticle

Brasil, Oswaldo Ferreira Moura ; Smith, Scott D. ; Galor, Anat ; Lowder, Careen Y. ; Sears, Jonathan E. ; Kaiser, Peter K. / Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema : An optical coherence tomography study. In: British Journal of Ophthalmology. 2007 ; Vol. 91, No. 6. pp. 761-765.
@article{9302a1a5156f46558a99b96f2dda3a34,
title = "Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: An optical coherence tomography study",
abstract = "Aim: To evaluate the predictive factors for visual outcome after intravitreal triamcinolone acetonide injection to treat refractory diabetic macular oedema (DME). Methods: A retrospective chart review of patients with DME who met the following inclusion criteria was performed: clinically significant diabetic macular oedema, receipt of a 4 mg/0.1 ml intravitreal triamcinolone acetonide injection and an optical coherence tomography (OCT) of the macula performed up to 10 days before injection. All patients received a full ophthalmic examination including best-corrected Snellen visual acuity (VA). The main outcome measure was the mean change in vision 3 months after injection. Results: Data from 73 eyes of 59 patients were analysed. After a mean follow-up of 324 days, the mean change in vision was -0.075 logarithm of minimum angle of resolution (logMAR) units, with 27.3{\%} improving ≥3 lines, 6.8{\%} declining ≥3 lines and 60.2{\%} remaining stable within 1 line of baseline vision. Statistical analysis was performed using multivariate generalised estimating equations on the basis of data from 52 eyes of 42 patients. Factors associated with an improvement in vision 3 months after injection were worse baseline VA (-0.27 logMAR units/unit increase in baseline VA, p = 0.002) and presence of subretinal fluid (-0.17 logMAR units, p = 0.06). The presence of cystoid macular oedema negatively affected the visual outcome (0.15 logMAR units, p = 0.03). In addition, the presence of an epiretinal membrane (ERM) was associated with less visual improvement. ERM modified the effect of baseline VA as demonstrated by a significant interaction between these two variables (0.34 logMAR units/unit increase in baseline VA, p = 0.04). Conclusions: OCT factors and baseline VA can be useful in predicting the outcomes of VA 3 months after intravitreal triamcinolone acetonide injection in patients with refractory DME.",
author = "Brasil, {Oswaldo Ferreira Moura} and Smith, {Scott D.} and Anat Galor and Lowder, {Careen Y.} and Sears, {Jonathan E.} and Kaiser, {Peter K.}",
year = "2007",
month = "6",
day = "1",
doi = "10.1136/bjo.2006.105783",
language = "English",
volume = "91",
pages = "761--765",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema

T2 - An optical coherence tomography study

AU - Brasil, Oswaldo Ferreira Moura

AU - Smith, Scott D.

AU - Galor, Anat

AU - Lowder, Careen Y.

AU - Sears, Jonathan E.

AU - Kaiser, Peter K.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Aim: To evaluate the predictive factors for visual outcome after intravitreal triamcinolone acetonide injection to treat refractory diabetic macular oedema (DME). Methods: A retrospective chart review of patients with DME who met the following inclusion criteria was performed: clinically significant diabetic macular oedema, receipt of a 4 mg/0.1 ml intravitreal triamcinolone acetonide injection and an optical coherence tomography (OCT) of the macula performed up to 10 days before injection. All patients received a full ophthalmic examination including best-corrected Snellen visual acuity (VA). The main outcome measure was the mean change in vision 3 months after injection. Results: Data from 73 eyes of 59 patients were analysed. After a mean follow-up of 324 days, the mean change in vision was -0.075 logarithm of minimum angle of resolution (logMAR) units, with 27.3% improving ≥3 lines, 6.8% declining ≥3 lines and 60.2% remaining stable within 1 line of baseline vision. Statistical analysis was performed using multivariate generalised estimating equations on the basis of data from 52 eyes of 42 patients. Factors associated with an improvement in vision 3 months after injection were worse baseline VA (-0.27 logMAR units/unit increase in baseline VA, p = 0.002) and presence of subretinal fluid (-0.17 logMAR units, p = 0.06). The presence of cystoid macular oedema negatively affected the visual outcome (0.15 logMAR units, p = 0.03). In addition, the presence of an epiretinal membrane (ERM) was associated with less visual improvement. ERM modified the effect of baseline VA as demonstrated by a significant interaction between these two variables (0.34 logMAR units/unit increase in baseline VA, p = 0.04). Conclusions: OCT factors and baseline VA can be useful in predicting the outcomes of VA 3 months after intravitreal triamcinolone acetonide injection in patients with refractory DME.

AB - Aim: To evaluate the predictive factors for visual outcome after intravitreal triamcinolone acetonide injection to treat refractory diabetic macular oedema (DME). Methods: A retrospective chart review of patients with DME who met the following inclusion criteria was performed: clinically significant diabetic macular oedema, receipt of a 4 mg/0.1 ml intravitreal triamcinolone acetonide injection and an optical coherence tomography (OCT) of the macula performed up to 10 days before injection. All patients received a full ophthalmic examination including best-corrected Snellen visual acuity (VA). The main outcome measure was the mean change in vision 3 months after injection. Results: Data from 73 eyes of 59 patients were analysed. After a mean follow-up of 324 days, the mean change in vision was -0.075 logarithm of minimum angle of resolution (logMAR) units, with 27.3% improving ≥3 lines, 6.8% declining ≥3 lines and 60.2% remaining stable within 1 line of baseline vision. Statistical analysis was performed using multivariate generalised estimating equations on the basis of data from 52 eyes of 42 patients. Factors associated with an improvement in vision 3 months after injection were worse baseline VA (-0.27 logMAR units/unit increase in baseline VA, p = 0.002) and presence of subretinal fluid (-0.17 logMAR units, p = 0.06). The presence of cystoid macular oedema negatively affected the visual outcome (0.15 logMAR units, p = 0.03). In addition, the presence of an epiretinal membrane (ERM) was associated with less visual improvement. ERM modified the effect of baseline VA as demonstrated by a significant interaction between these two variables (0.34 logMAR units/unit increase in baseline VA, p = 0.04). Conclusions: OCT factors and baseline VA can be useful in predicting the outcomes of VA 3 months after intravitreal triamcinolone acetonide injection in patients with refractory DME.

UR - http://www.scopus.com/inward/record.url?scp=34249825200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249825200&partnerID=8YFLogxK

U2 - 10.1136/bjo.2006.105783

DO - 10.1136/bjo.2006.105783

M3 - Article

C2 - 17108013

AN - SCOPUS:34249825200

VL - 91

SP - 761

EP - 765

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 6

ER -